Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients.

This systematic review and meta-analysis examined the relationship between a broad spectrum of biomarkers and clinical factors with sepsis-induced coagulopathy (SIC). The analysis pooled data from studies involving a total population of 37,459 patients. The research aimed to determine which specific markers, including glycocalyx degradation, fibrinogen, albumin, neutrophil extracellular traps, microparticles, lactate, thrombomodulin, procalcitonin, APACHE II score, and C-reactive protein, were statistically associated with the occurrence of SIC. The study design aggregated existing evidence to provide a comprehensive overview of potential predictive indicators in this complex clinical setting.

The intervention or exposure in this analysis consisted of the presence or levels of the aforementioned biomarkers and clinical scores. The comparator was the absence of these markers or normal baseline levels within the context of sepsis. Specific dosing or administration protocols were not applicable as the study focused on observational associations rather than therapeutic interventions. The primary outcome measured was the statistical association between these markers and the diagnosis or presence of sepsis-induced coagulopathy.

Primary outcome results indicated significant associations for several key markers. Glycocalyx degradation demonstrated a significant association with SIC, with an effect size of 11.85 and a 95% confidence interval of 8.59-16.34. Reduced levels of fibrinogen were associated with SIC, showing an effect size of 4.35 and a 95% CI of 2.47-7.69. Similarly, reduced levels of albumin were linked to SIC, with an effect size of 2.5 and a 95% CI of 1.82-3.45. Neutrophil extracellular traps showed an association with SIC, yielding an effect size of 2.4 and a 95% CI of 1.81-3.19. Increased circulating levels of microparticles were also associated with SIC, with an effect size of 1.61 and a 95% CI of 1.33-1.95. Elevated lactate levels were associated with SIC, presenting an effect size of 1.18 and a 95% CI of 1.13-1.23. Thrombomodulin levels were associated with SIC, with an effect size of 1.10 and a 95% CI of 0.97-1.26. For procalcitonin, APACHE II score, and C-reactive protein, the analysis noted predictive value for SIC occurrence, but specific effect sizes, absolute numbers, and p-values or confidence intervals were not reported in the available data.

Secondary outcomes were not explicitly detailed in the provided data beyond the primary associations. Safety and tolerability findings were not reported for the biomarkers themselves, as the study design was observational and did not involve the administration of these substances. Consequently, data on adverse events, serious adverse events, discontinuations, and general tolerability are unavailable. The study did not evaluate the safety of using these markers in clinical practice.

Comparisons to prior landmark studies in the therapeutic area of sepsis and coagulopathy were not explicitly detailed in the input data. However, the identification of these specific markers aligns with current understanding of the pathophysiology of sepsis, where endothelial damage and inflammatory cascades play central roles. The meta-analysis approach allows for a broader synthesis of evidence than individual studies, potentially increasing the robustness of the observed associations.

Key methodological limitations include the inherent nature of observational data, which precludes establishing direct causal links between the markers and the development of SIC. The results should be interpreted as statistical associations rather than direct causal mechanisms. Potential biases related to study heterogeneity, varying measurement methods for biomarkers, and differences in patient populations across the included studies may influence the pooled estimates. Further prospective trials are needed to confirm the clinical utility of these markers in guiding patient management.

Clinical implications suggest that these markers may assist clinicians in the early recognition of high-risk patients with sepsis-induced coagulopathy. Identifying patients with reduced fibrinogen, albumin, or evidence of glycocalyx degradation could prompt closer monitoring or earlier intervention. However, because the evidence identifies statistical associations and not causal relationships, these markers should not be used in isolation for definitive diagnosis or treatment decisions without further validation. The lack of reported safety data does not imply harm but rather reflects the observational nature of the study.

Several questions remain unanswered regarding the optimal timing for measuring these markers, their performance in specific subpopulations of sepsis patients, and their incremental value over existing clinical scores. The predictive value for procalcitonin, APACHE II score, and C-reactive protein was noted, but the lack of reported effect sizes and confidence intervals limits the precision of their contribution to risk stratification. Future research must address these gaps to determine how best to integrate these findings into standard sepsis care protocols.